CHRS Quote, Financials, Valuation and Earnings

Inovio Pharmaceuticals, Inc. has a net margin of -363.56% compared to Coherus Oncology, Inc.'s net margin of -30140.49%. Coherus Oncology, Inc.'s return on equity of -- beat Inovio Pharmaceuticals, Inc.'s return on equity of -257.94%.

Coherus Oncology, Inc. has a consensus price target of $6.75, signalling upside risk potential of 304.19%. On the other hand Inovio Pharmaceuticals, Inc. has an analysts' consensus of $7.63 which suggests that it could grow by 626.98%. Given that Inovio Pharmaceuticals, Inc. has higher upside potential than Coherus Oncology, Inc., analysts believe Inovio Pharmaceuticals, Inc. is more attractive than Coherus Oncology, Inc..

Coherus Oncology, Inc. has a beta of 1.033, which suggesting that the stock is 3.258% more volatile than S&P 500. In comparison Inovio Pharmaceuticals, Inc. has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.745%.

Coherus Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coherus Oncology, Inc. pays -- of its earnings as a dividend. Inovio Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Coherus Oncology, Inc. quarterly revenues are $12.7M, which are larger than Inovio Pharmaceuticals, Inc. quarterly revenues of --. Coherus Oncology, Inc.'s net income of -$46.3M is lower than Inovio Pharmaceuticals, Inc.'s net income of $3.8M. Notably, Coherus Oncology, Inc.'s price-to-earnings ratio is 1.06x while Inovio Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus Oncology, Inc. is 4.65x versus 745.40x for Inovio Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -363.56% compared to Coherus Oncology, Inc.'s net margin of 20.83%. Coherus Oncology, Inc.'s return on equity of -- beat Johnson & Johnson's return on equity of 34.46%.

Coherus Oncology, Inc. has a consensus price target of $6.75, signalling upside risk potential of 304.19%. On the other hand Johnson & Johnson has an analysts' consensus of $241.71 which suggests that it could grow by 1.19%. Given that Coherus Oncology, Inc. has higher upside potential than Johnson & Johnson, analysts believe Coherus Oncology, Inc. is more attractive than Johnson & Johnson.

Coherus Oncology, Inc. has a beta of 1.033, which suggesting that the stock is 3.258% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.29%.

Coherus Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.2% to investors and pays a quarterly dividend of $1.30 per share. Coherus Oncology, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Coherus Oncology, Inc. quarterly revenues are $12.7M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Coherus Oncology, Inc.'s net income of -$46.3M is lower than Johnson & Johnson's net income of $5.1B. Notably, Coherus Oncology, Inc.'s price-to-earnings ratio is 1.06x while Johnson & Johnson's PE ratio is 21.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus Oncology, Inc. is 4.65x versus 6.08x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of -363.56% compared to Coherus Oncology, Inc.'s net margin of -165.45%. Coherus Oncology, Inc.'s return on equity of -- beat Nektar Therapeutics's return on equity of -364.32%.

Coherus Oncology, Inc. has a consensus price target of $6.75, signalling upside risk potential of 304.19%. On the other hand Nektar Therapeutics has an analysts' consensus of $128.13 which suggests that it could grow by 68.06%. Given that Coherus Oncology, Inc. has higher upside potential than Nektar Therapeutics, analysts believe Coherus Oncology, Inc. is more attractive than Nektar Therapeutics.

Coherus Oncology, Inc. has a beta of 1.033, which suggesting that the stock is 3.258% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.165, suggesting its more volatile than the S&P 500 by 16.45%.

Coherus Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coherus Oncology, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Coherus Oncology, Inc. quarterly revenues are $12.7M, which are smaller than Nektar Therapeutics quarterly revenues of $21.8M. Coherus Oncology, Inc.'s net income of -$46.3M is lower than Nektar Therapeutics's net income of -$36.1M. Notably, Coherus Oncology, Inc.'s price-to-earnings ratio is 1.06x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus Oncology, Inc. is 4.65x versus 93.08x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis, Inc. has a net margin of -363.56% compared to Coherus Oncology, Inc.'s net margin of -64%. Coherus Oncology, Inc.'s return on equity of -- beat Stereotaxis, Inc.'s return on equity of -191.14%.

Coherus Oncology, Inc. has a consensus price target of $6.75, signalling upside risk potential of 304.19%. On the other hand Stereotaxis, Inc. has an analysts' consensus of $4.20 which suggests that it could grow by 127.03%. Given that Coherus Oncology, Inc. has higher upside potential than Stereotaxis, Inc., analysts believe Coherus Oncology, Inc. is more attractive than Stereotaxis, Inc..

Coherus Oncology, Inc. has a beta of 1.033, which suggesting that the stock is 3.258% more volatile than S&P 500. In comparison Stereotaxis, Inc. has a beta of 1.428, suggesting its more volatile than the S&P 500 by 42.77%.

Coherus Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coherus Oncology, Inc. pays -- of its earnings as a dividend. Stereotaxis, Inc. pays out -- of its earnings as a dividend.

Coherus Oncology, Inc. quarterly revenues are $12.7M, which are larger than Stereotaxis, Inc. quarterly revenues of $8.6M. Coherus Oncology, Inc.'s net income of -$46.3M is lower than Stereotaxis, Inc.'s net income of -$5.5M. Notably, Coherus Oncology, Inc.'s price-to-earnings ratio is 1.06x while Stereotaxis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coherus Oncology, Inc. is 4.65x versus 5.07x for Stereotaxis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.